Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Source: 
Reuters
snippet: 

Alexion Pharmaceuticals Inc (ALXN.O) said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.